In the latest trading session,, 1.09 million Xeris Biopharma Holdings Inc (NASDAQ:XERS) shares changed hands as the company’s beta touched 1.04. With the company’s most recent per share price at $3.86 changed hands at -$0.27 or -6.53% at last look, the market valuation stands at $594.25M. XERS’s current price is a discount, trading about -57.25% off its 52-week high of $6.07. The share price had its 52-week low at $1.69, which suggests the last value was 56.22% up since then. When we look at Xeris Biopharma Holdings Inc’s average trading volume, we note the 10-day average is 4.0 million shares, with the 3-month average coming to 2.82 million.
Analysts gave the Xeris Biopharma Holdings Inc (XERS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended XERS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Xeris Biopharma Holdings Inc’s EPS for the current quarter is expected to be -0.04.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Instantly XERS was in red as seen in intraday trades today. With action -25.04%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 13.87%, with the 5-day performance at -25.04% in the red. However, in the 30-day time frame, Xeris Biopharma Holdings Inc (NASDAQ:XERS) is -12.07% down. Looking at the short shares, we see there were 11.21 million shares sold at short interest cover period of 3.4 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 22.8% from its recent market value. According to analyst projections, XERS’s forecast low is 4 with 6.6 as the target high. To hit the forecast high, the stock’s price needs a -70.98% plunge from its current level, while the stock would need to soar -3.63% for it to hit the projected low.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
Year-over-year growth is forecast to reach 29.17% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 57.61M. 6 analysts are of the opinion that Xeris Biopharma Holdings Inc’s revenue for the current quarter will be 62.65M. The company’s revenue for the corresponding quarters a year ago was 40.64M and 48.06M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 41.76%. The estimates for the next quarter sales put growth at 30.35%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 40.01%. The 2025 estimates are for Xeris Biopharma Holdings Inc earnings to increase by 83.57%.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.04% of Xeris Biopharma Holdings Inc shares while 42.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 44.61%. There are 42.81% institutions holding the Xeris Biopharma Holdings Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 6.9649% of the shares, roughly 10.33 million XERS shares worth $23.25 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.4492% or 7.66 million shares worth $17.23 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 4.22 shares estimated at $16.31 million under it, the former controlled 2.74% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.33% of the shares, roughly 3.58 shares worth around $13.84 million.
